C07C279/04

Polyguanidine polymers and methods of use thereof

Polyguanidines and methods of use thereof are described. In particular, polyguanidines of formula (I), formula (II), and formula (III) are described. The polyguanidines can be used to treat infection, such as bacterial, viral or fungal infection, and as an ex vivo microbial agent. ##STR00001##

Polyguanidine polymers and methods of use thereof

Polyguanidines and methods of use thereof are described. In particular, polyguanidines of formula (I), formula (II), and formula (III) are described. The polyguanidines can be used to treat infection, such as bacterial, viral or fungal infection, and as an ex vivo microbial agent. ##STR00001##

Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use

Provided herein are nitrite salts of 1,1-dimethylbiguanide; and isotopic variants thereof; and pharmaceutically acceptable hydrates and solvates thereof. Also provided herein are their pharmaceutical compositions and methods of use for treating, preventing, or ameliorating one or more symptoms of diseases associated with and/or caused by an abnormal blood glucose level. Further provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a cardiovascular disease.

Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use

Provided herein are nitrite salts of 1,1-dimethylbiguanide; and isotopic variants thereof; and pharmaceutically acceptable hydrates and solvates thereof. Also provided herein are their pharmaceutical compositions and methods of use for treating, preventing, or ameliorating one or more symptoms of diseases associated with and/or caused by an abnormal blood glucose level. Further provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a cardiovascular disease.

Hydrotropic composition and its uses

A hydrotropic composition including at least one surface active cationic component, which is selected from a group of cholinium, guadinium or tetramethylguadinium, preferably cholinium, and a straight or branched carboxylate anion having at least six carbon atoms and its uses, for treating of oil sands or the like, for treating tailings from separation of bitumen, asphaltenes or the like.

Surfactant composition and method for treating bitumen froth

The invention relates to a surfactant composition comprising an ionic liquid prepared from an unsubsituted or substituted primary, secondary or tertiary amine, or from an unsubstituted or substituted pyridine, amidine or guanidine with at least one fatty acid and/or resin acid. The invention also relates to a method for treating bitumen froth from a separation process, where bitumen is separated from mineral solids. The method comprises addition of said surfactant composition to the diluent and/or to the froth before phase separation.

Imidazole-based compounds as hepatitis C virus inhibitors

Imidazole-based compounds as hepatitis C virus (HCV) inhibitors. The compounds have an imidazole core that is disubstituted via amide links. Also described are a pharmaceutical composition incorporating the imidazole-based compound, a method of preparing these compounds, and a method for using the pharmaceutical composition in the treatment of HCV infection.

Cationic lipids for nucleic acid delivery and preparation thereof

The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids.

Cationic lipids for nucleic acid delivery and preparation thereof

The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids.

COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS

The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in .sup.18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.